Announced Date: 2020-09-04 (September 04, 2020)<\/p>\n\n\n\n
Asset Name: Lemzoparlimab (TJC4)<\/p>\n\n\n\n
Licensor (Seller): I-MAB\u00a0Biopharma (China)<\/p>\n\n\n\n
Licensee (Buyer): AbbVie<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Asset Modality: monoclonal antibody<\/p>\n\n\n\n
Asset Target: CD47<\/p>\n\n\n\n
Potential Indication: solid tumor<\/p>\n\n\n\n
Stage until the deal: Phase 1<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Scope of Authority:<\/p>\n\n\n\n
AbbVie will be granted an exclusive global license, excluding greater\u00a0China, to develop and commercialize lemzoparlimab. <\/p>\n\n\n\n
I-Mab retains all rights to develop and to commercialize lemzoparlimab in mainland\u00a0China,\u00a0Macau\u00a0and\u00a0Hong Kong. <\/p>\n\n\n\n
Both companies will collaborate to design and conduct further global clinical trials to evaluate lemzoparlimab in multiple cancers. <\/p>\n\n\n\n
.<\/p>\n\n\n\n
The collaboration also allows for potential collaboration on future CD47-related therapeutic agents. Each party will have the opportunity subject to further licenses to explore each other’s related programs in their respective territories.<\/p>\n\n\n\n
The companies will share manufacturing responsibilities with AbbVie being the primary manufacturer for global supply. The collaboration will accelerate I-Mab’s establishment of commercial production operations in China.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Payment Detail:<\/p>\n\n\n\n
AbbVie will pay I-Mab\u00a0$180 million\u00a0in an upfront payment to exclusively license lemzoparlimab, <\/p>\n\n\n\n
along with\u00a0$20 million\u00a0in a milestone payment based on the Phase 1 results, for a total of\u00a0$200 million. <\/p>\n\n\n\n
In addition, I-Mab will be eligible to receive up to\u00a0$1.74 billion\u00a0in success-based milestone payments for lemzoparlimab, of which\u00a0$840 million\u00a0are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. <\/p>\n\n\n\n
Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China.\u00a0\u00a0\u00a0<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Link:<\/p>\n\n\n\n